Hypothalamic pituitary adrenal axis hormone changes during IL-17A inhibition with secukinumab in patients with psoriasis
Secukinumab treatment in psoriasis is accompanied by HPA axis activation. Further studies are needed to determine the duration, mechanisms, and magnitude of this activation.
Authors
- Frederik Krefting
- Manfred Schedlowski (ORCID: https://orcid.org/0000-0002-9968-9770)
- Wiebke Sondermann (ORCID: https://orcid.org/0000-0002-3684-3523)
- Stefanie Hölsken (ORCID: https://orcid.org/0000-0001-6756-6963)
Institutions
- Essen University Hospital (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Clinical Immunology
- Published
- 2025-10-18
- DOI
- https://doi.org/10.1016/j.clim.2025.110611
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00